Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Input metadata referenced "Vericel Corp," but the filing text identifies the registrant as Aastrom Biosciences, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2006
Business Stage: Development stage company focused on proprietary adult bone marrow-derived cell-based therapeutics (Tissue Repair Cells or TRCs) for tissue regeneration. The company has no commercial sales organization and relies on grants, limited product sales, and equity financing.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2006 | Nine Months Ended Mar 31, 2006 | Balance Sheet (Mar 31, 2006) |
|---|---|---|---|
| Total Revenues | $238,000 | $535,000 | - |
| Net Loss | $(4,549,000) | $(12,179,000) | - |
| Net Loss Per Share (Basic/Diluted) | $(0.04) | $(0.12) | - |
| Cash and Cash Equivalents | - | - | $12,838,000 |
| Short-Term Investments | - | - | $9,500,000 |
| Total Current Assets | - | - | $22,980,000 |
| Total Current Liabilities | - | - | $1,697,000 |
| Accumulated Deficit | - | - | $(137,854,000) |
Revenue Composition (Nine Months 2006): Grants ($393,000) and Product Sales/Rentals ($142,000).
Operating Expenses (Nine Months 2006): Research & Development ($6,745,000); Selling, General & Administrative ($6,711,000).
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased to $535,000 for the nine months ended March 31, 2006, from $813,000 in the prior year period. Product sales dropped significantly ($142,000 vs. $377,000) due to reduced volume of therapy kit sales for clinical trials.
- Expense Increase: Total costs and expenses rose to $13,467,000 (nine months 2006) from $9,625,000 (nine months 2005).
- R&D: Increased to $6,745,000 due to expanded clinical trials (bone grafting, vascular repair) and staffing.
- SG&A: Increased to $6,711,000 driven by executive search costs (CEO, Board, Marketing Director), performance bonuses, and legal costs.
- Accounting Change: Adoption of SFAS 123R (Share-Based Payment) on July 1, 2005, resulted in non-cash stock compensation charges of $288,000 in R&D and $503,000 in SG&A for the nine-month period.
- Liquidity: Cash and short-term investments decreased by approximately $10.1 million from June 30, 2005, primarily due to operating cash burn of $10.3 million.
Guidance, Outlook, and Risks
Outlook and Capital Needs:
- Management expects available cash (including a subsequent $24 million equity raise in April 2006) to fund operations beyond June 30, 2007.
- Monthly cash utilization is estimated at approximately $1.3 million for the remainder of fiscal 2006.
- The company does not expect positive cash flow from operations for several years.
Clinical Progress:
- Bone Regeneration: U.S. Phase I/II trials for long bone fractures showed healing in initial patients; EU trials in Spain showed positive results. A new trial for jaw bone reconstruction is underway.
- Osteonecrosis: Received FDA Orphan Drug Designation in March 2006; preparing clinical protocols.
- Vascular: Pilot trial for diabetic limb ischemia initiated in Germany.
Key Risks:
- Regulatory: New EU directives may delay trials or require Marketing Authorization. FDA approval is required for U.S. commercialization.
- Financial: Dependence on equity financing; risk of stock dilution and potential delisting from Nasdaq if bid price falls below $1.00.
- Operational: Reliance on third-party suppliers for manufacturing components and animal-derived materials (e.g., fetal bovine serum).
- Management Transition: CEO R. Douglas Armstrong is transitioning out of day-to-day management; a search for a successor is underway.
Investor Verification Checklist
- Subsequent Financing: Verify the closing and terms of the $24 million registered direct placement announced in April 2006.
- Cash Runway: Confirm current cash burn rate against the $1.3 million monthly estimate to validate the "beyond 2007" liquidity claim.
- Regulatory Status: Monitor the impact of new EU Medicinal Products directives on the timeline for European clinical trials.
- CEO Succession: Track the progress of the search for a new Chief Executive Officer.
- Stock Price: Monitor compliance with Nasdaq minimum bid price requirements ($1.00) to assess delisting risk.